股骨成形术能否改善髋关节镜的长期临床结局与生存率?一项至少15年随访研究
本研究为回顾性队列研究,比较单纯髋关节镜治疗与联合股骨成形术治疗孤立性凸轮型股骨髋臼撞击征的长期结局。联合股骨成形术组末次改良Harris髋关节评分更高(82.7 vs 64.7,P=0.002),15年无全髋关节置换生存率(78% vs 41%,P=0.02)和无再手术生存率(78% vs 29%,P=0.003)均更优。作者认为长期数据强烈支持对凸轮型股骨髋臼撞击征患者行股骨成形术,并提示该治疗改变了疾病的自然史。
要点
- 联合股骨成形术组末次改良Harris髋关节评分82.7,显著高于单纯髋关节镜组的64.7(P=0.002)。
- 联合股骨成形术组15年无全髋关节置换生存率78%,显著高于单纯髋关节镜组的41%(P=0.02)。
- 联合股骨成形术组15年无再手术生存率78%,显著高于单纯髋关节镜组的29%(P=0.003)。
核心结论
- 与单纯髋关节镜相比,关节镜联合股骨成形术治疗凸轮型股骨髋臼撞击征的长期临床结局与生存率更优。
- 这些长期数据强烈支持对凸轮型股骨髋臼撞击征形态患者行股骨成形术,并提示该治疗在长期随访中改变了股骨髋臼撞击征的自然史。
研究设计与样本
- 回顾性队列研究,证据等级3级,纳入连续两个队列的孤立性凸轮型股骨髋臼撞击征患者。
- 单纯髋关节镜组(HS组)17髋,随访19.7±1.2年;关节镜联合股骨成形术组(HS-OST组)23髋,随访16.0±0.6年。
- 两个队列建立于本研究中心在采用股骨成形术治疗股骨髋臼撞击征前后的不同过渡时间点。
- 临床结局采用改良Harris髋关节评分(mHHS)评估,采用Kaplan-Meier分析评估无全髋关节置换生存率和无再手术生存率。
主要发现
- 两组间患者特征或形态学差异均无统计学显著差异。
- HS-OST组末次mHHS为82.7,HS组为64.7(P=0.002);HS-OST组mHHS改善18.4,HS组改善6.1(P=0.02)。
- HS-OST组15年无全髋关节置换生存率78%,HS组为41%(P=0.02)。
- HS-OST组无再手术生存率78%,HS组为29%(P=0.003)。
关键数值与推荐
- 末次mHHS:HS-OST组82.7 vs HS组64.7(P=0.002)。
- mHHS改善:HS-OST组18.4 vs HS组6.1(P=0.02)。
- 15年无全髋关节置换生存率:HS-OST组78% vs HS组41%(P=0.02)。
- 无再手术生存率:HS-OST组78% vs HS组29%(P=0.003)。
临床怎么用
- 作者认为,长期数据强烈支持对凸轮型股骨髋臼撞击征形态患者行股骨成形术。
- 作者提示,该治疗在长期随访中改变了股骨髋臼撞击征的自然史。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although femoral osteoplasty is common practice in treating cam-type femoroacetabular impingement (FAI), long-term data are lacking that support the ability of this procedure to optimize outcomes and alter natural history. PURPOSE: To compare long-term clinical outcomes and survivorship of treatment for symptomatic FAI via arthroscopic correction of labral or chondral pathology with and without femoral osteoplasty. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: A retrospective cohort study was performed across 2 consecutive cohorts of patients with isolated cam-type FAI who underwent hip arthroscopic treatment of labral or chondral pathology without femoral osteoplasty (HS group) or with femoral osteoplasty (HS-OST group). These unique cohorts were established at a distinct transition time in our practice before and after adoption of femoral osteoplasty for treatment of FAI. Clinical outcomes were measured using the modified Harris Hip Score (mHHS). Kaplan-Meier analysis was used to assess for total hip arthroplasty (THA)-free and reoperation-free survivorship. RESULTS: The final HS group included 17 hips followed for 19.7 ± 1.2 years, and the final HS-OST group included 23 hips followed for 16.0 ± 0.6 years. No significant patient or morphological differences were found between groups. Compared with the HS group, the HS-OST group had significantly higher final mHHS (82.7 vs 64.7 for HS-OST vs HS, respectively; P = .002) and mHHS improvement (18.4 vs 6.1; P = .02). The HS-OST group also had significantly greater 15-year THA-free survivorship versus the HS group (78% vs 41%, respectively; P = .02) and reoperation-free survivorship (78% vs 29%; P = .003). CONCLUSION: This study demonstrated superior long-term clinical outcomes and survivorship with combined arthroscopy and femoral osteoplasty compared with hip arthroscopy alone. These long-term data strongly support the practice of femoral osteoplasty in patients with cam FAI morphologies and suggest that this treatment alters the natural history of FAI at long-term follow-up.
引用
- Nepple JJ, Parilla FW, Ince DC, et al. Does Femoral Osteoplasty Improve Long-term Clinical Outcomes and Survivorship of Hip Arthroscopy? A 15-Year Minimum Follow-up Study. Am J Sports Med. 2022. PMID: 36178189. doi:10.1177/03635465221123048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。